AIMS: ABCB1, some ABCCs and SLCOs have been reported to affect the intracellular accumulation of various protease inhibitors in vitro and ex vivo. Darunavir is the most recently licensed protease inhibitor and we sought to investigate the ability of transport inhibitors to influence its intracellular accumulation in lymphocytes from healthy volunteers. METHODS: The intracellular accumulation of radiolabelled darunavir was assessed using CEM cells and ABCB1-overexpressing CEM(VBL) cells. Apical and basolateral transport of radiolabelled darunavir through MDCKII monolayers was also studied. Finally the ability of known inhibitors to influence intracellular accumulation of darunavir in peripheral blood mononuclear cells (PBMC) was investigated. RESULTS: CEM(VBL) cells (1.4 +/- 0.6, P < 0.001, 95% CI for the difference = 0.46, 0.80, n= 7) had significantly lower accumulation of darunavir compared with CEM cells (5.6 +/- 0.7, n= 7) and this was reversed by addition of tariquidar (30 nm, 4.6 +/- 0.8, P < 0.001, 95% CI =-0.64, -0.41, n= 4). In MDCKII-ABCBI cells, transport from the basal to the apical compartment was observed and this was also reversible with the addition of tariquidar. In PBMCs, dipyridamole (6.9 +/- 1.3, P < 0.01, 95% CI for the difference =-1.16, -0.30, (n= 8) significantly increased whilst montelukast (5.7 +/- 1.0, P < 0.01, 95% CI for the difference = 0.16, 0.79, n= 8) significantly decreased the intracellular accumulation of darunavir when compared with control (6.2 +/- 1.1, n= 8). CONCLUSIONS: Darunavir is a substrate for efflux and influx transporters in PBMC and intracellular concentrations can be manipulated using known inhibitors.
AIMS: ABCB1, some ABCCs and SLCOs have been reported to affect the intracellular accumulation of various protease inhibitors in vitro and ex vivo. Darunavir is the most recently licensed protease inhibitor and we sought to investigate the ability of transport inhibitors to influence its intracellular accumulation in lymphocytes from healthy volunteers. METHODS: The intracellular accumulation of radiolabelled darunavir was assessed using CEM cells and ABCB1-overexpressing CEM(VBL) cells. Apical and basolateral transport of radiolabelled darunavir through MDCKII monolayers was also studied. Finally the ability of known inhibitors to influence intracellular accumulation of darunavir in peripheral blood mononuclear cells (PBMC) was investigated. RESULTS: CEM(VBL) cells (1.4 +/- 0.6, P < 0.001, 95% CI for the difference = 0.46, 0.80, n= 7) had significantly lower accumulation of darunavir compared with CEM cells (5.6 +/- 0.7, n= 7) and this was reversed by addition of tariquidar (30 nm, 4.6 +/- 0.8, P < 0.001, 95% CI =-0.64, -0.41, n= 4). In MDCKII-ABCBI cells, transport from the basal to the apical compartment was observed and this was also reversible with the addition of tariquidar. In PBMCs, dipyridamole (6.9 +/- 1.3, P < 0.01, 95% CI for the difference =-1.16, -0.30, (n= 8) significantly increased whilst montelukast (5.7 +/- 1.0, P < 0.01, 95% CI for the difference = 0.16, 0.79, n= 8) significantly decreased the intracellular accumulation of darunavir when compared with control (6.2 +/- 1.1, n= 8). CONCLUSIONS:Darunavir is a substrate for efflux and influx transporters in PBMC and intracellular concentrations can be manipulated using known inhibitors.
Authors: M Horio; K V Chin; S J Currier; S Goldenberg; C Williams; I Pastan; M M Gottesman; J Handler Journal: J Biol Chem Date: 1989-09-05 Impact factor: 5.157
Authors: E Bakos; R Evers; G Szakács; G E Tusnády; E Welker; K Szabó; M de Haas; L van Deemter; P Borst; A Váradi; B Sarkadi Journal: J Biol Chem Date: 1998-11-27 Impact factor: 5.157
Authors: J Ford; E R Meaden; P G Hoggard; M Dalton; P Newton; I Williams; S H Khoo; D J Back Journal: J Antimicrob Chemother Date: 2003-08-13 Impact factor: 5.790
Authors: Dennis W Schneck; Bruce K Birmingham; Julie A Zalikowski; Patrick D Mitchell; Yi Wang; Paul D Martin; Kenneth C Lasseter; Colin D A Brown; Amy S Windass; Ali Raza Journal: Clin Pharmacol Ther Date: 2004-05 Impact factor: 6.875
Authors: Ekaterina Taneva; Kerry Crooker; Sung Hyun Park; Jonathan T Su; Adina Ott; Natalia Cheshenko; Igal Szleifer; Patrick F Kiser; Bruce Frank; Pedro M M Mesquita; Betsy C Herold Journal: Antimicrob Agents Chemother Date: 2015-12-28 Impact factor: 5.191
Authors: Omar Janneh; Patrick G Bray; Elizabeth Jones; Christoph Wyen; Peter Chiba; David J Back; Saye H Khoo Journal: J Antimicrob Chemother Date: 2010-03-17 Impact factor: 5.790
Authors: Ekaterina Taneva; Shada Sinclair; Pedro Mm Mesquita; Brian Weinrick; Scott A Cameron; Natalia Cheshenko; Kerry Reagle; Bruce Frank; Sujatha Srinivasan; David Fredricks; Marla J Keller; Betsy C Herold Journal: JCI Insight Date: 2018-07-12
Authors: Balázs Könnyű; S Kashif Sadiq; Tamás Turányi; Rita Hírmondó; Barbara Müller; Hans-Georg Kräusslich; Peter V Coveney; Viktor Müller Journal: PLoS Comput Biol Date: 2013-06-06 Impact factor: 4.475